• Worldwide Auctioneers is renowned for its elite slate of vintage motorcar auctions for classic car collection enthusiasts
• The 14th annual Auburn Auction takes place in Auburn, Indiana, the birthplace of the collector car auction industry
• The Denny “Kannonball” Kannenberg Collection Auction features the lifetime collection of Kannenberg, a celebrated flat-track racer

An impressive gathering of vintage cars offered without reserve and one of the most significant motorcycle collections to ever come to market make Worldwide Auctioneers’ next two auctions highly distinguishable. Worldwide Auctioneers, a wholly owned subsidiary of Perpetual Industries (OTC: PRPI), has become renowned for the sale and acquisition of vintage motorcars, and its elite slate of auctions are can’t-miss events for classic car collection enthusiasts. Scheduled for Sept. 4, 2021, Worldwide Auctioneers’ next auction — its 14th annual Auburn Auction — takes place in Auburn, Indiana, the birthplace of the collector car auction industry. The event will be offered simultaneously live and online, allowing car aficionados everywhere to participate. The auction features one of Worldwide Auctioneers’ most exclusive lists of offerings yet, including outstanding prewar automobiles, select muscle cars, American and European sportscars, classics and racers, as well as an exceptional selection of the best automobilia and memorabilia to be found  (https://ibn.fm/d3qYQ). Some of the highly desirable cars offered during the event include a 1934 Packard Twelve Individual sedan and a 1934 Packard 1208 Custom Convertible sedan, both with custom coachwork by Dietrich; a 1960 Omega Jaguar test driven by famed Sir Jackie Stewart; and a 1984 Ferrari 512 Bbi only 5,000 miles from new. In addition, Worldwide Auctioneers also announced the Denny “Kannonball” Kannenberg Collection Auction, scheduled for Sept. 10–11 (https://ibn.fm/oprmi). Also held in Auburn, this all no-reserve auction will be presented by Gas Monkey Garage and Richard Rawlings and features the lifetime collection of Kannenberg, a celebrated flat-track racer. This prestigious two-day event is particularly noteworthy because it showcases one of the most significant motorcycle collections to ever come to market. Included among this collection of special bikes is the rare 1942 Indian Four “440,” complete with original sidecar; a 1986 Honda CX500 Turbo that was presented by Honda to the king of drag racing, “Big Daddy” Don Garlits; and the infamous 1969 Kawasaki 500 III, nicknamed the Widow Maker and with a well-earned reputation for being terrifyingly fast. A video is available showcasing the entire collection, with Richard Rawlings and Denny Kannonball (https://ibn.fm/Z7v5Z). “Trying to choose even a couple of favorite motorcycles from this unbelievable selection is impossible,” said Worldwide Auctioneers’ principal and auctioneer John Kruse. “We’re honored to have been entrusted with the sale of this historic collection and look forward to bringing it to a global audience of collectors and enthusiasts.” Perpetual Industries is an incubator for the development of new and innovative energy-efficient technologies. The company’s mission is to “perpetuate industry” by bringing value-added technologies to market. The company is expanding its expertise and knowledge of energy-efficient technology by developing low-cost, green-energy-powered solutions for a variety of industries while continuing its research, development and commercialization of the XYO Technology in key applications. For more information, visit the company’s website at www.PerpetualIndustries.com. NOTE TO INVESTORS: The latest news and updates relating to PRPI are available in the company’s newsroom at https://ibn.fm/PRPI

• CHALF appoints retail veteran Ginger Mollo as chief integration officer, Fifth & Root GM
• Mollo will oversee the positioning, expansion of the Fifth & Root Brand within the health and wellness beauty market as well as integration into Chalice brands
• Chalice has engaged MP-IMC to heighten profile of Fifth & Root in Chalice Brands product portfolio

Chalice Brands (CSE: CHAL) (OTCQB: CHALF), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, has appointed retail veteran Ginger Mollo as chief integration officer for the company. In addition, Mollo will also serve as general manager of Fifth & Root, a nationally recognized CBD skin-care brand based in California. Both appointments are effective immediately. “We are thrilled to add Ginger, the woman who had her fingertips on Apple stores, bring us her high-achieving, goal-focused, and innovative mover and shaker expertise, with over 20 years of retail experience to Fifth & Root,” said Chalice CEO and president Jeff Yapp. “We look forward to benefitting from Ginger’s experience in the progressive retail space to elevate the structure and style of Fifth & Root to the next level. She brings many years of interpersonal communication, collaborative problem solving and critical thinking to the leadership team.” In her new roles, Mollo will oversee the positioning and expansion of the Fifth & Root Brand within the health and wellness beauty market as well as integrating the products within the Chalice brands. Earlier this year, Chalice Brands, then Golden Leaf Holdings Ltd., closed on its purchase of majority ownership in Fifth & Root, which is available online and in major retailers including Ulta Beauty, Nordstrom, Anthropologie and Urban Outfitters (https://ibn.fm/47HbZ). “The acquisition of these distribution channels greatly increases the company’s visibility and reach, and continues to advance our ‘Crawl, Walk, Run’ strategic approach,” said Yapp. “As we look forward to the eventual federal legalization of cannabis, Fifth & Root’s commerce platform and partnerships will position the company favorably to capitalize on the evolving marketplace.” Mollo brings extensive experience with her; she has held several positions in retail and company development at companies such as Limited Brands and Apple. At Apple, she was an integral part of the team that helped create the iconic Apple Stores, then pivoted into leading stores and regions as well as creating and managing all functions of Apple’s global training organization. In addition, Chalice has retained MP-Integrated Marketing Communications (MP-IMC) to provide public relations, marketing communications and brand-building support services to Fifth & Root. The company has built an impressive reputation for everything from product development to sustained growth and offers a bicoastal team to support the growth and consumer engagement of its clients. “We are pleased to announce that we have engaged MP-IMC to heighten the profile of Fifth & Root in our Chalice Brands product portfolio,” stated Yapp. “We look forward to working with Melissa and her team to enhance the essence of Fifth & Root.” Chalice Brands is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with 12 dispensaries in Portland, Oregon. The company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Chalice operates nationally through Fifth and Root and has operations in Oregon and California. For more information, visit the company’s website at www.ChaliceBrandsLtd.com. NOTE TO INVESTORS: The latest news and updates relating to CHALF are available in the company’s newsroom at https://ibn.fm/CHALF

• InMed has a world class leadership team with a successful track record of drug development and commercialization
• The company recently announced closing of a $12 million private placement
• InMed has a solid and expanding intellectual property portfolio with multiple patents filed
• The company recently signed an LOI to acquire rare cannabinoids manufacturer BayMedica
• InMed retains all commercial rights to its IntegraSyn manufacturing system
• InMed has filed clinical trial applications in several countries as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa
• The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029

InMed Pharmaceuticals (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids. The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer. Research and Technology There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (“CBN”) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”). Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (“API”) in InMed’s two lead programs for dermatological and ocular diseases. InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021. InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye. Manufacturing The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods. BayMedica Inc. Acquisition On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids. As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year. Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period. Market Outlook There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids. Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more. Management Team Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany). Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc. Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc. Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto. Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• Augmented reality market solutions developer Nextech AR Solutions is pioneering the use of three-dimensional holograms for video conferencing and product placement
• Nextech expects to launch its platform for providing 3D versions of digital NFT collectibles during the current third quarter
• The company is not only working to create 3D NFTs, it is in talks with existing marketplaces to use its acquired Threedy.AI 3D content creation technology to turn existing NFT artwork into AR NFTs at scale
• The NFT market’s value tripled last year and rose an additional 1,785 percent during this year’s first quarter

The NFT marketplace has caught the imagination of consumers during the past year and a half, boosting the valuation of the digital collectibles in tandem with the COVID-19 worldwide pandemic as people have spent more time than ever online, workers have placed a new priority on personal passions and new startups have made buying and selling collectibles online easier than before (https://ibn.fm/TFp7L). As a result, the NFT market’s value tripled in 2020, achieving $250 million before 2021 kicked the trending digital assets into a new class of matrix with a 1,785 percent increase in market cap during Q1 (https://ibn.fm/1AiYQ). Augmented reality (“AR”) ecosystem innovator Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF) is jumping into the deep end of the NFT pool with its three-dimensional product IP, which it hopes will send NFT excitement even higher as it creates a type of collectible digital asset new to the burgeoning marketplace. “This venture is an exciting step forward for Nextech and a big move for creators and consumers alike,” Dawsyn Borland, the company’s vice president of AR Innovation Labs and Content stated in Nextech’s July 26 press release (https://ibn.fm/JONVM). “AR experiences are extremely well positioned as NFTs, as they not only display digital content but allow buyers to interact with them. Our current technology stack is perfectly in line with the global adoption of NFTs and we are thrilled to meet this growing demand.” NFTs are trade-able digital economy products — virtual representations of artistic works that are in a sense owned electronically by consumers but not copyrighted, similar to a mass-produced baseball card or poster that gains collectible value according to its rarity, the presence of an autograph and other factors — ultimately determining its value simply by what someone is willing to spend on it in comparison with any similar products held by other collectors. Nextech’s experience with AR innovations includes work in projecting human holograms and commercial products to cell phones and other smart tech devices in the form of 3D visualizations. Nextech’s human hologram creator platform HoloX is expected to launch during the current third quarter, which will provide the ecosystem for seamless interaction with the digital collectibles in augmented reality (https://ibn.fm/5x6IE). The NFTs will initially be purchased through a third-party marketplace so they can be accessed outside a digital wallet using HoloX, but Nextech then aims to establish its own platform where the human hologram NFTs can be bought, sold and “minted,” which is the process of obtaining revenue from an NFT by turning the digital art into a part of the Ethereum blockchain as a public ledger. In the same way that the process of creating coins is called minting, the addition of NFTs to a blockchain to make the artwork tamper-proof and trade-able is known as minting (https://ibn.fm/BJ9Cu). Nextech is also working on agreements to turn existing NFT artwork into AR NFTs at scale for placement in existing marketplaces, thanks to 3D content creation capabilities the company gained through its recent acquisition of Threedy.AI. Nextech’s single integrated platform for creating and delivering thousands of 3D models per week will help increase the reach of the NFT market. The company expects to provide additional details about its NFT in August. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

• Upon acquiring Mulch Manufacturing last year, Sustainable Green Team was established as an integrated group of companies
• SGTM has robust infrastructure designed to alleviate landfill burden from downed trees by processing them into mulch sold to government, residential, commercial clients
• After posting $30.58 million in revenue in FY 2021, SGTM started Q1 on forward looking 12-month run rate of $37.16 million in revenue, $5.6 million in gross profit

How can a tree in a populous Tampa subdivision end up as decorative soft mulch outside a home in Iowa? Easier than one might think through the infrastructure of Sustainable Green Team (OTC: SGTM) and its portfolio of subsidiaries specialized in tree services, debris hauling, biomass recycling, and manufacture of next-generation mulch products as well as specialty cypress lumber. Sustainable Green Team’s vertically integrated operations include Central Florida Arborcare, National Storm Recovery LLC, and Mulch Manufacturing Inc., three brands that speak quite clearly to the corporate mission to reduce environmental impact through responsible handling of tree debris rather than burying it in already over-burdened landfills. Earlier this month, the miraculous wind power of hurricanes was once again on full display, as Hurricane Elsa, the first Atlantic hurricane of 2021, ripped through Barbados and all the way up the U.S.’s East Coast. A Category 1 hurricane, Elsa was just a toddler compared to a giant like Category 5 hurricane Katrina that flattened New Orleans in 2005, killing over 1,800 people and damaging an estimated 320 million large Gulf Coast trees (https://ibn.fm/FotZB). Regardless of a hurricane’s designation, clean-up can take months to complete. Nobody talks much about removal of all the trees and debris in the wake of a storm, but when they go to a landfill, the storm’s negative impact on the planet just gets amplified. That’s where the expertise of SGTM comes in. Through its subsidiaries and list of governmental, residential and commercial clients, the clean-up is efficient and green. From a mobile command center assessing the damage and plotting a clean-up strategy to truck and rail logistics to create and move feedstock to one of its six production facilities to its retail and wholesale end consumers, SGTM can handle it all. With distribution across the country, that downed tree in Florida will end up a productive part of the economy again—potentially around a prairie rose in Iowa. Sustainable Green Team under its current moniker and operations has only been around a little over one year.  After acquiring Mulch Manufacturing in February 2020 (https://ibn.fm/ZD1Xn), a rebranding transpired to better represent the direction of the integrated group of companies. To that end, 2021 got off to a promising start ahead of the start of its hurricane system. During the quarter ended January 31, 2021 (which caught the final month of the 2020 hurricane season), the company reported revenue of $4.55 million and a gross loss of $752,792. The quarterly gross loss was a bit of an outlier considering SGTM reported $30.58 million in revenue and $3.51 million in gross profit for the full year. In the first quarter, ended April 30, 2021, the numbers jumped to $9.29 million in revenue and $1.4 million in gross profit. On forward-looking basis, that would extrapolate to a run rate of $37.16 million in revenue and $5.6 million in gross profit over the full year. Based upon reporting history, investors will have to wait until somewhere around early September to see how performance went during the quarter that ends July 31, 2021. That quarter includes the June 1 kickoff of the current hurricane season, while the company moves into the only quarter completely comprised of hurricane months in what is expected to be a busy year for storm activity. For more information, visit the company’s website at www.CentralFloridaArborcare.com. NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• The 2021 International Gaming Awards is set to take place September 8, 2021, at the Savoy Hotel in London
• These prestigious awards feature the very best and brightest operators in the global gaming industry
• Mobius Interactive is a finalist in the RISING STAR OF THE YEAR category

Mobius Interactive, an online gaming operator launched in September 2020, has been nominated for an award at the 2021 International Gaming Awards at the Savoy Hotel in London (https://ibn.fm/0ms9r). The International Gaming Awards (“IGA”) is an annual charity-focused event that that brings together the very best and brightest companies in the global iGaming industry, to celebrate the innovation, ingenuity, and success of their craft. Mobius Interactive is proud to announce that their company is a finalist in the RISING STAR OF THE YEAR category. The other nominees for the Rising Star of the Year Award include: BGaming, Boyd Gaming Group, Feed Construct, Funky Games, Just For The Win, Slotmill, VBET and Wheelz Casino. This sponsored event raises money for both local and international charities. One of these sponsors is UltraPlay, a leading eSports and iGaming platform and a key partner of Mobius Interactive. The main charitable beneficiary of the International Gaming Awards is CARE International, one of the world’s leading humanitarian and development organizations. CARE International works in 74 poor and developing countries to tackle the underlying causes of poverty and foster self-sufficiency. The IGA has raised over $350,000 USD for CARE to date. This highly-attended international awards ceremony usually takes place in February, but given pandemic restrictions, this year it was moved to September 8. This was a fortuitous move — with COVID restrictions now lifted in Great Britain, the IGA is excited to host this annual event in an atmosphere of normalcy, and the awards ceremony can once again embrace the socially-exuberant environment for which it is known. Mobius Interactive CEO Lynn Pearce, a key contributor to Infinity Magazine, is very excited, both about the nomination and attending the awards ceremony. “We are so happy to announce that we are finalists in the International Gaming Awards category of Rising Star of the Year 2021. Thanks so much to our excellent, hardworking Operations and Marketing teams for this honour. The team at Mobius Interactive is looking forward to this exciting event. Fingers crossed for the win!” Mobius Interactive’s three main brands: Mobius.bet, Club Double , and Aragon Casino target multiple geographical areas and customer segments around the world. Partnered with over 750 VIP and Master Gaming Affiliates, Mobius Interactive, with its award-winning platforms, is taking the iGaming industry to the next level, strategically targeting key markets through world class partners, an eSports focus, expert gamification, innovative loyalty programs, and premium customer relationship management. Mobius Interactive is open for investment opportunities. For further information please contact: Gary Eldridge – President 1 (604) 783-1685  gary@mobiusinteractive.ltd Seamus Byrne – VP Corporate Development 1 (902) 441-5757  seamus.byrne@halifaxcitrus.ca  For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• ACP’s strategy is based on leveraging opportunities in real estate and licensing in states that have recently passed legalization legislation
• Focused on complementary business segments — real estate, acquisition and development of proprietary assets, and ongoing cultivation operations, ACP appears poised for expansion
• Company seeks partnerships with companies with aligned personal, ethical, and business sensibilities to differentiate itself in assets, services, research, and philanthropy

American Cannabis Partners (“ACP”) is a licensed, large-scale, and 100% organic cultivation company supplying multiple forms of raw product at consistent wholesale prices for manufacturing, distribution, and retail licenses. The company is considering additional growth via numerous initiatives, including expansion opportunities through partnerships and joint ventures in New Jersey, New York, Virginia, Nevada, Arizona, Missouri, and Massachusetts (https://ibn.fm/7WK0A). American Cannabis Partners strives to operate the business in a way that positively impacts the environment, employees, customers, and partners alike. For example, as a high-paying grower, ACP takes its role in the local community very seriously. The company prides itself on its close personal and positive relationship with Jamaica and its people, one founded in profound awareness of needs and not just business numbers. The company is committed to taking a similar approach to building relationships with its partners, striving to build synergistic relationships and position itself as a reliable business ally. The experience of business partners working with ACP clearly reflects this commitment. In the words of Sam Deyton of Soilscape Solutions, a company helping rejuvenate soil fertility through sustainable soil practices, the experience of collaborating with ACP is exceptional. “Working with Stephen, Gary, and the rest of the team at American Cannabis Partners has been amazing. At Soilscape Solutions, we appreciate forming mutually beneficial relationships with our clients in the cultivation field, especially those whose core values align with our own. American Cannabis Partners brings integrity, professionalism, and small business values to the table in every way they conduct their business; it has been our pleasure to earn their business in return”, he said in a statement shared with the company. Link4 Corporation CEO Stephen Scherer, a company manufacturing software and environmental controls for growers, also praises the experience of collaborating with ACP. “Link4 Corporation is excited to be working with ACP in bringing environmental automation to all of their Greenhouse locations across the United States. It is always important for growers to not only monitor their grow environments closely but also have the ability to compare, track, and graph the data and relationships between different harvests. This is especially true when an MSO like American Cannabis Partners is working on strain development. We are pleased to hear that through ACP’s utilization of the Link4 Cloud, they feel they have everything they need to ensure their environment is operating within ideal parameters”, he described his collaboration with ACP in a testimonial recently shared with the company. Partnerships like these can produce exceptional results, and the words of American Cannabis Partners COO Gary Coltek, attest to this. “Having industry partners like Soilscapes and Link4 Systems have made it possible to replicate exact soil conditions, growing supplements, water makeup, and environments that mimic Orange Hill in Jamaica. The level of detail given to our plants have resulted in yields well above industry norms, and producing some of the most sought after flower in the US, especially our new patent-pending strains under the brand name ZUK where the entire crop has been pre-sold for 2021”, said Coltek. His views about the importance of strong business partnerships are shared by the company’s CEO Stephen Jordan. “Working with Soilscapes has provided us with an anomaly in the cannabis industry, consistent supply. One of the most difficult parts of the industry is locking down a supplier that provides various options tailored to a company’s needs. Soilscapes did that for ACP from nutrients, soil, greenhouse, and irrigation material”, he shared his experience of working with one of the company’s partners recently. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• InnerScope Hearing Technologies prepares to launch first in a series of National Hearing Loss Blitz Media Campaigns to raise hearing problems awareness and showcase company’s unique hearing aid solutions as US government pushes for more accessible hearing aids market
• Campaign expected to drive sales of its revolutionary Direct-to-Consumer, rechargeable app-controlled hearing aids and other services such as subscription plans which allow patients access to a complete set of affordable hearing aids for less than $45 per month
• InnerScope Hearing Technologies remains committed to improving quality of life for 70 million people in North America who suffer from hearing impairment and potentially 1.5 billion worldwide

InnerScope Hearing Technologies (OTC: INND) appears poised to disrupt the traditional hearing technology space by making affordable hearing aid technology accessible for affected patients across America and potentially beyond. The company has announced the launch of its efforts to contribute to the National Hearing Loss Blitz Media Campaign in a commitment to reach 48 million Americans suffering from hearing issues who can benefit from its unique Direct-to-Consumer technology (https://ibn.fm/u4BbJ). As an emerging disruptive leader in the hearing industry, InnerScope is planning more national multimedia marketing campaigns over the next months to generate public awareness about the hearing loss problem and help consumers control their growing hearing issues. The company teamed up with New to The Street TV, the partner trusted with the production, broadcasting, and distribution of marketing collateral about hearing loss awareness and InnerScope’s Direct-to-Consumer Bluetooth app-controlled, self-adjusting rechargeable hearing aids that give patients access to hearing treatments without the need of medical professionals. Hearing loss is a growing problem affecting a significant number of Americans. According to the Centers for Disease Control and Prevention, around 16% of the adults in the US have hearing issues, twice as many as some other prevailing diseases such as diabetes or cancer (https://ibn.fm/GbyZO). But since hearing aids are so expensive — on average, they cost more than $5,000 per pair — only 14% of patients can afford them. This problem recently prompted an executive order from President Biden to make hearing aids more affordable and available over the counter without any prior medical evaluation (https://ibn.fm/V6eOW). Today, many patients are unaware that direct-to-consumer hearing aids are available online without any medical evaluation — and InnerScope is poised to get this message out as a company offering affordable and timely hearing aid solutions to patients across the US. Through the campaign, the company aims to put a spotlight on the importance of early treatment while showcasing its game-changing Direct-to-Consumer hearing aids and its new Hearing Health Flexible Subscription Plans. These easy-to-enroll plans allow patients to order a complete set of InnerScope’s Direct-to-Consumer rechargeable app-controlled hearing aids with no prior medical examination or professional help. The campaign, intended to include 156 digital billboards throughout lower Manhattan, New York City, New York, and TV commercials to be broadcast on prominent media outlets such as Bloomberg, CNN, CNBC, Fox Business Network, Fox News, MSNBC, and Newsmax TV, is expected to drive sales of InnerScope’s hearing aids, available online through its digital store. Poised to shift hearing health care from expensive traditional brick-and-mortar hearing care clinics to consumers’ homes, InnerScope targets a sizable market that includes around 70 million patients with hearing-related problems across North America. In addition, the global addressable market counts 1.5 billion people suffering from hearing impairment or hearing-related issues around the world. For more information, visit the company’s website at www.INND.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection
• The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people approach cancer screening
• CDA is powered by a database of over 200,000 samples and cases, providing a new way to approach disease and cancer screening
• The company’s management team comprises professionals in both the United States and China who are knowledgeable and well educated in cancer screening and detection
• The global cancer diagnostics market is expected to reach $249.6 billion by 2026

AnPac Bio-Medical Science Co. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance. AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is situated in Philadelphia, Pennsylvania. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States. Cancer Differentiation Analysis (“CDA”) Cancer Differentiation Analysis (“CDA”) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form. Most liquid-based cancer screening and detection technologies focus on biochemical signals, like conventional biomarkers and genomic signals, such as ct-DNAs and CTCs (circulating tumor cells in the blood). These typically only determine whether or not cancer has occurred at a fixed point in time. CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future – all through a standard blood test, at a competitive price point. AnPac Bio-Medical’s CDA is powered by a database of over 200,000 samples and cases and serves as a new way to approach disease and cancer screening. The device uses an integrated system of sensors to detect several biophysical signals at the cellular, protein and molecular levels. CDA leverages a proprietary algorithm to synthesize the data, effectively generating a personalized risk assessment for evaluated patients. Through CDA technology, AnPac Bio-Medical aims to address a number of goals, including:

• Innovate – AnPac Bio-Medical is an innovator in the cancer screening industry, with CDA research ongoing since 2008, and commercial operations beginning in 2015. AnPac considers itself a thought leader in developing multi-cancer screening.
• Detect – AnPac Bio-Medical detects early signals of threatening cancer and its location within the body.
• Identify – CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity rates.
• Provide – The company’s platform provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms, which results in accurate and easy-to-understand results.
• Proven – A fully operational analysis of over 200,000 test samples has been run to date. CDA technology has been shown to identify pre- and early-stage cancers in patients previously diagnosed as “cancer-free” through traditional methods.
• Biophysical Properties – CDA analyzes biophysical properties in human blood and the correlation between biophysical properties and cancer occurrence.

Market Outlook AnPac Bio-Medical is exploring detection of other types of cancers leveraging its innovative CDA technology and multi-cancer screening and detection tests, which could open significant opportunities on the global cancer diagnostics market. According to a report by Grand View Research, the cancer diagnostics market is expected to reach $249.6 billion worldwide by 2026 (https://ibn.fm/EMdoS). The market is expected to grow at a CAGR of 7% during the forecast period. Management Team Dr. Chris Yu is the Co-Founder and Chief Executive Officer of AnPac Bio-Medical. He has enjoyed a successful career as an innovator in life sciences, technology and engineering. Dr. Yu has worked for three U.S. Fortune 500 companies and is the first/principal inventor of over 300 patent applications spanning semiconductors, materials and life science. He has a proven history of developing cutting-edge products with long-term profit and sustainability. Dr. Yu was born to a medical doctor’s family and went to medical school. He later switched his major to physics and received his bachelor’s and master’s degrees in physics from the University of Missouri-Kansas City Campus and a doctoral degree in physics from Pennsylvania State University. Both of his dissertations addressed innovative detection techniques. Dr. Herbert Yu is the Co-Founder and Chief Medical Officer of AnPac Bio-Medical. He is a renowned expert in molecular epidemiology, with training in medicine and chemical biochemistry. Dr. Yu has a 20-year career in leading-edge cancer research, including breakthrough work in areas of carcinogenic factors. He is a professor and research director at the University of Hawaii and an adjunct professor at Yale University. He received his bachelor’s degree in medicine from Shanghai First Medical College. Dr. Yu also received a science degree in epidemiology and a Ph.D. in clinical biochemistry from the University of Toronto. Jingiu (Edward) Tang is the company’s Chief Financial Officer. He previously served as a global internal auditor at Natuzzi S.p.A. Mr. Tang also worked at Beijing Dongshen CPA and Shanghai De’an CPA, providing external audits, finance and tax advisory services across different industries and sectors. He is a Certified Public Accountant in Australia. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University, and his bachelor’s degree in law from Southwest University of Science and Technology in China. Weidong Dai is the company’s China General Manager. He previously served as a general partner at Stirrfir Investment Management Co. Mr. Dai has also served as the chairman of RTS Management (Shanghai) Co., and as managing director of Hong Kong Pro-Health Technology Co. and Shanghai Pro-Health Medical Devices Co. He has published a number of medical research papers and research articles in professional journals. Mr. Dai was awarded the Hong Kong Industrial Award for a medical device that he led in research and development. He earned his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from the Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics. For more information, visit the company’s website at www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

• Emaginos is first company with actionable plan to transform, improve public schools rather than replace them
• The company has support from both major U.S. teachers’ unions
• Emaginos filed a provisional patent application for its proprietary EdManage platform

In a space where investment windows are few and far between, Emaginos offers a unique opportunity for altruistic individuals to change the educational landscape (please see website if interested in investing). The company, which is raising capital from the general investing public under provisions of Regulation A, is seeking $3 million to implement its proven, patent-pending K-12 education system and transform the nation’s educational system. “Emaginos is the first company with an actionable plan to transform and improve public schools rather than replace them,” the company explains (https://ibn.fm/VkLX5). “The Emaginos model utilizes existing funding, facilities and staff to improve educational approaches and outcomes, in many cases saving school districts money as they subscribe to and implement the Emaginos platform.” And while the Emaginos system is designed to ultimately help schools and districts save money, the company is also working to ensure its investors may realize return on their investments. As schools adopt the system, the cost to implement the program decreases while an increasing number of schools climb aboard. “Our solution is a subscription service,” explains Emaginos president Allan Jones (https://ibn.fm/qcfgH). “We have no local district executives collecting outrageous salaries. The teachers run the schools using the tools and resources provided by Emaginos. For a reasonable fee, Emaginos provides a comprehensive suite of services that empowers and enables the school district to transform itself into an engaging learning environment. The districts still control their schools. For the same money they were spending on a defective program, we enable them to deliver a high-quality education.” The Emaginos system is gaining support — and momentum. The company reports that it has support from both major U.S. teachers’ unions, the American Federation of Teachers and the National Education Association. That backing strengthens the company’s position as it moves forward toward widespread marketing and implementation of the Emaginos model in public schools throughout the United States. In addition, the company recently has filed a provisional patent application with the United States Patent and Trademark Office for its proprietary EdManage platform, an educational technology (edtech) analytics platform that aggregates and analyzes all of a school district’s data to deliver actionable information to users throughout the system (https://ibn.fm/TpQG9). EdManage integrates all of the devices and applications within a school system that traditionally operate independently. Emaginos is a company dedicated to transforming K-12 public schools into a model composed of integrated, proven best practices. The company opposes replacing public schools with charter schools or damaging public schools by draining resources through vouchers or school choice programs. Emaginos firmly believes in restoring the concept of the neighborhood schools as the center of the community. To achieve this vision, Emaginos begins by transforming an initial school in the district into a charter school as a model for the transformation. The charter model, in this instance, uses the concept as it was intended, to test and demonstrate the effectiveness and efficacy of a new model in the district. After the model is successful in the charter school, the lessons learned are used to directly transform the rest of the schools into effective public schools. For more information about Emaginos and to learn about investment and shareholder opportunities, visit www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos